

Spiration<sup>™</sup> Valve System Humanitarian Use Device for Management of Air Leaks



# Introduction

**Important Notice to Readers:** This document is intended to help physicians, hospitals and ambulatory surgery centers better understand coding, billing, coverage policies and reimbursement methodologies for bronchial air leak valve procedures that involve Olympus bronchoscopy equipment.

The information presented here is for illustrative purposes only and does not constitute reimbursement or legal advice. The reimbursement information provided by Olympus America Inc. and/or its direct or indirect (through one or more intermediaries) parent companies, affiliates or subsidiaries (collectively, the "Olympus Group") is gathered from third-party sources and is subject to change without notice. Reimbursement rules vary widely by insurer so you should understand and comply with any specific rules that may be set by the patient's insurer. You must also understand and comply with Medicare's complex rules. It is the provider's sole responsibility to determine medical necessity and in turn identify the appropriate codes, charges, and modifiers for services rendered to submit accurate claims. It is the provider's sole responsibility to determine medical necessity and to in turn identify which CPT codes to report and to submit accurate claims. You should always consult with your local payers regarding reimbursement matters. Under no circumstances shall the Olympus Group or its employees, consultants, agents or representatives be liable for costs, expenses, losses, claims, liabilities or other damages (whether direct, indirect, special, incidental, consequential or otherwise) that may arise from or be incurred in connection with this information or any use thereof.

Coding recommendations, coverage policies, and reimbursement rates and methodologies vary by payer and are updated frequently. Providers should review applicable payer guidelines and instructions to ensure that billing practices comply with the payer's requirements and contact the payer if they have any questions.

The American Medical Association (AMA) is responsible for development and maintenance of Current Procedural Terminology (CPT<sup>®</sup>) codes. Providers should check the complete AMA CPT reference manual and/or another authoritative source for a complete listing of all CPT codes and their descriptors. It is the provider's responsibility to report the code(s) that accurately describes the procedure(s) furnished and the patient's diagnosis. Please note that the presence of a code, or billing a particular code, is not a guarantee of payment. Reimbursement will vary for each provider based on a number of factors, including the payer, site of service, geographic location and contractual terms.

CPT is a registered trademark of the American Medical Association. Copyright 2022-2023, American Medical Association, all rights reserved. Applicable FARS/DFARS apply to government use.

© 2022 Olympus America Inc.

# Humanitarian Device for Use in the Control of Prolonged Air Leaks

# HUD/HDE Status

A Humanitarian Use Device (HUD) is a medical device intended to benefit patients in the treatment or diagnosis of a disease or condition that affects or is manifested in fewer than 8,000 individuals in the United States per year.

Spiration applied for and received U.S. Food and Drug Administration (FDA) designation as a HUD and received Humanitarian Device Exemption (HDE) approval for the use of its minimally invasive Spiration Valve System to control prolonged air leaks of the lung or significant air leaks that are likely to become prolonged, following lobectomy, segmentectomy and Lung Volume Reduction Surgery (LVRS). FDA approval of an HDE authorizes the applicant to market a HUD subject to certain conditions of approval.

# **Indication for Use**

The Spiration Valve System is indicated to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged air leaks, following lobectomy, segmentectomy and Lung Volume Reduction Surgery (LVRS). An air leak present on post-operative day 7 is considered prolonged unless present only during forced exhalation or cough. An air leak present on day 5 should be considered for treatment if it is: 1) continuous, 2) present during normal inhalation phase of inspiration, or 3) present upon normal expiration and accompanied by subcutaneous emphysema or respiratory compromise. The Spiration Valve System use is limited to 6 weeks per prolonged air leak.

# Caution

Humanitarian Device. Authorized by Federal Law for use in the control of prolonged air leaks of the lung or significant air leaks that are likely to become prolonged following lobectomy, segmentectomy or Lung Volume Reduction Surgery (LVRS). The effectiveness of this device for this use has not been demonstrated. Federal law restricts this device to sale by or on the order of a physician.

- Contraindications: Patient is unable to tolerate a flexible bronchoscopy procedure. Allergy to latex and nickel.
- Warnings: Atelectasis may occur after the air leak seals and patients should be monitored for this possible complication.
- **General Precautions:** The Spiration Valve System should not be used for patients who have active asthma, bronchitis or clinically significant bronchiectasis. Only use a bronchoscope with a working channel of 2.6 mm or larger. Do not use the Spiration Valve System for other than its intended use.
- **Potential Adverse Effects:** Atelectasis; Death; Infection in the tissue distal to a valve; Local airway swelling or edema at site of valve implantation; Pneumothorax.
- For full prescribing information please see the Supporting Documentation Section of this guide.

# Spiration Valve Procedure Overview for Air Leak

Postoperative air leaks continue to be the most common complication following lung resection surgery and a leading cause of increased hospitalization, morbidity and cost. Postoperative air leaks that are present 5-7 consecutive days following the surgery are typically classified as "prolonged" air leaks.<sup>1</sup> Conventional management of prolonged air leaks involves chest drainage and observation followed by more invasive treatments when leaks do not resolve.<sup>1</sup>

The Spiration Valve System is the only FDA approved device indicated to control prolonged air leaks of the lung following lobectomy, segmentectomy and Lung Volume Reduction Surgery (LVRS). The Spiration valves are inserted proximal to an air leak through a minimally invasive bronchoscopic procedure. Once in place the one way valve limits distal airflow. The reduction of airflow may facilitate the resolution of the air leak.

# Inpatient Hospital Coding and Reimbursement

The Centers for Medicare & Medicaid Services (CMS) assigns discharges to Medicare Severity Diagnosis Related Groups (MS-DRGs) that determine inpatient reimbursement. Inpatient MS-DRG assignment and reimbursement is determined by ICD-10-PCS procedure code selection and ICD-10-CM primary and secondary diagnosis code related to the inpatient admission.

# ICD-10-PCS Endobronchial Valve Procedure Codes

Hospitals use ICD-10-PCS procedure codes to describe procedures performed on inpatients. The table below identifies potential ICD-10-PCS procedure codes that may be used to describe the insertion and removal of the endobronchial valve(s). Hospitals are responsible for accurately selecting ICD-10-PCS procedure codes to describe the procedures performed during an inpatient stay.

The ICD-10-PCS procedure codes listed in this table are not intended to be an exhaustive list of all possible hospital procedure codes.

Potential ICD-10-PCS Procedure Codes for Spiration Valve System			
ICD-10-PCS Code	ICD-10-PCS Description		
Valve Placement			
0BH38GZ	Insertion of Endobronchial Valve into Right Main Bronchus, Via Natural or Artificial Opening Endoscopic		
0BH48GZ	Insertion of Endobronchial Valve into Right Upper Lobe Bronchus, Via Natural or Artificial Opening Endoscopic		
0BH58GZ	Insertion of Endobronchial Valve into Right Middle Lobe Bronchus, Via Natural or Artificial Opening Endoscopic		
0BH68GZ	Insertion of Endobronchial Valve into Right Lower Lobe Bronchus, Via Natural or Artificial Opening Endoscopic		
0BH78GZ	Insertion of Endobronchial Valve into Left Main Bronchus, Via Natural or Artificial Opening Endoscopic		
0BH88GZ	Insertion of Endobronchial Valve into Left Upper Lobe Bronchus, Via Natural or Artificial Opening Endoscopic		
0BH98GZ	Insertion of Endobronchial Valve into Lingula Bronchus, Via Natural or Artificial Opening Endoscopic		
0BHB8GZ	Insertion of Endobronchial Valve into Left Lower Lobe Bronchus, Via Natural or Artificial Opening Endoscopic		
Valve Removal			
0WPQ8YZ	Removal of Other Device from Respiratory Tract, Via Natural or Artificial Opening Endoscopic		

<sup>1</sup>Mahajan AK, Doeing DC, Hogarth DK. Isolation of persistent leaks and placement of intrabronchial valves. J Thorac Cardiovasc Surg 2013;145:626-30

# **ICD-10-CM Diagnosis Codes**

The Spiration Valve System is indicated for the control of prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged following lobectomy, segmentectomy, and Lung Volume Reduction Surgery (LVRS). Hospitals and physicians should check with payers for clinical application of diagnosis codes for payment and coverage. Applicability and usage of these codes may vary per case.

The ICD-10-CM diagnosis codes listed in this table are not intended to be an exhaustive list of all possible diagnosis codes.

Potential ICD-10-CM Diagnosis Codes for Air Leaks		
ICD-10-CM Code	ICD-10-CM Description	
J93.0	Spontaneous tension pneumothorax	
J93.11	Primary spontaneous pneumothorax	
J93.12	Secondary spontaneous pneumothorax	
J93.81	Chronic pneumothorax	
J93.82	Other air leak	
J93.83	Other pneumothorax	
J93.9	Pneumothorax, unspecified	
J95.811	Postprocedural pneumothorax	
J95.812	Postprocedural air leak	

# Medicare Severity Diagnosis Related Groups (MS-DRGs)

The MS-DRG assignment will be influenced by the primary and secondary diagnosis codes reported for the stay along with other procedures that may be performed. Medicare will adjust reimbursement according to case severity which for many MS-DRGs consist of a family of 3 codes pertaining to the level of complication or comorbitities seen during the inpatient stay. The secondary diagnosis codes are used to make the determination of severity.

CMS has designated the EBV insertion procedure codes as affecting assignment to surgical MS-DRGs 163, 164 and 165 (Major Chest Procedures with MCC, with CC and without CC/MCC, respectively).<sup>2</sup>

Effective 10/1/19 Medicare inpatient EBV insertion procedure codes will be assigned to one of the three Major Chest Procedure MS-DRGs based on the claim submissions.

Below is the 2022 Medicare national inpatient reimbursement amount for MS-DRGs 163-165.

Medicare Inpatient Hospital Reimbursement			
MS-DRG	AS-DRG MS-DRG Title		
163	MAJOR CHEST PROCEDURES W MCC	\$33,016	
164	MAJOR CHEST PROCEDURES W CC	\$17,512	
165	MAJOR CHEST PROCEDURES W/O CC/MCC	\$12,639	

Source:

Inpatient Hospital: CMS-1752-F, Table 1A, 1D, and published 2021-8-13 Effective October 1,2021 through 09/30/2022.

Note: Specific crosswalks may vary from the Centers for Medicare & Medicaid Services' General Equivalency Mappings Inpatient payment amounts effective 10/1/2021 through 9/30/2022. MS DRG payment calculated with an average hospital base rate of \$6594.31. Base rate of \$6594.31 includes the national adjusted operating standardized amounts, labor 67.6% share and 32.4% non-labor share, for hospitals submitting quality and EHR data plus capital adjustment amounts. Represents National Average Medicare Fees (Without Geographic Adjustment) Last Updated December 2021.

<sup>2</sup>Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2021 Rates; Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting nteroperability Programs Requirements for Eligible Hospitals and Critical Access Hospitals, 84 Fed. Reg. 42144 (November 16, 2020)

# **Physician and Outpatient Hospital Coding and Reimbursement**

# **CPT<sup>®</sup> Coding Overview**

There are four Category I CPT codes to report bronchoscopy services for insertion and removal of bronchial valve(s) in CPT 2021 Professional Edition. The codes consist of a 2-code series for insertion (initial and each additional lobe), and a 2-code series for removal (initial and each additional lobe).

The Category I CPT codes are intended for billing on a per-lobe basis, including instances when multiple valves are placed within or removed from a single lobe. Physicians should consider all available coding options and select the appropriate CPT code based on the procedure(s) performed.

Below are the coding descriptions for the insertion and removal of bronchial valves.

2022 Medicare Physician and Outpatient Hospital Reimbursement			
CPT <sup>®</sup> Codes	CPT <sup>®</sup> Description	Physician Allowed Amount for Hospital/ASC	Hospital Outpatient Allowed Amount
31647	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertionof bronchial valve(s), initial lobe	\$209	\$5,947*
31651	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertionof bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure[s])	\$77	**
31648	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), initial lobe	\$200	\$3,164*
31649	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure)	\$68	\$1,528

Represents National Average Medicare Fees Without Geographic Adjustment. Updated January 2022. Rates effective January 1, 2022 through December 31, 2022.

Sources:

- CPT & Description: Copyright 2021 American Medical Association. All rights reserved. Applicable FARS/DFARS apply to government use.

- Medicare Physician Fee Schedule: CMS-1734-F, addendum B published November 19, 2021. Physician payment amounts based on \$34.6062 conversion factor effective 01/01/2022 through 12/31/2022. Physician Fee Schedule Procedures and Facility Payments may be subject to Medicare's Multiple Procedure Reduction Rules.

- Hospital Outpatient Fee Schedule: CMS-1751-FC, addendum B released November 2, 2021, effective 01/01/2022 through 12/31/2022.

\*J1 code status Outpatient Hospital C-APC procedure is a comprehensive APC limiting payment for other procedures performed that day.

\*\*Payment is packaged into the payment for 31647.

# **Spiration Valve System Frequently Asked Questions**

#### • Will payers cover this procedure for prolonged air leak patients?

Even though use of the Spiration Valve System requires IRB approval per the Humanitarian Use Device (HUD) guidelines, the Spiration Valve System is FDA-approved as HUD, and therefore can be billed to Medicare Administrative Contractors and commercial payers. Coverage will vary by insurer.

Absence of a formal coverage policy does not mean the technology or procedure is not covered. In the absence of a formal coverage policy, payers may provide coverage for services that are medically reasonable and necessary on a case-by-case basis. It is always a best practice to contact the insurance companies and determine patient benefits and coverage for a particular new technology or procedure.

A sample medical necessity letter is included in this guide to assist you in making the case to the payer as to why the procedure was medically necessary for an individual patient.

#### • What are the CPT<sup>®</sup> codes for bronchial valve insertion and/or removal?

There are four Category I CPT codes to report bronchoscopy services for the insertion and removal of bronchial valve(s). The codes consist of a 2-code series for insertion procedures (initial and each additional lobe) and a 2-code series for removal procedures (initial and each additional lobe).

These Category I CPT codes are intended for billing on a per-lobe basis, including instances when multiple valves are placed or removed from a single lobe.

• Can multiple CPT codes be reported when more than one valve is inserted or removed from a single lobe? No, the Category I CPT codes are intended for billing on a per-lobe basis, including instances when multiple valves are placed within or removed from a single lobe.

• Can balloon occlusion be billed separately in addition to the valve placement?

No, the insertion of bronchial valve CPT codes description includes balloon occlusion as part of the procedure.

• Are prior authorizations required for the Spiration Valve System?

Under Medicare, prior authorizations are not required for any procedure; however, your local Medicare contractor may have specific processes that require submission of materials before a case is performed and billed to your local Medicare contractor.

Commercial payers vary in their requirements for prior authorization for the Spiration Valve System. The provider should contact the patient's payer prior to performing any procedure that may require prior authorization.

• Are there Spiration Valve System materials that we can use in our discussions with payers?

Please see and review the detailed information in the Supporting Materials Section of this reimbursement guide.

• Does HCPCS code (or C code) C1889 (implantable/insertable device not otherwise classified) apply to the valve implanted for patients with air leaks?

Medicare guidance has determined that a device can be considered implantable if it is for single patient use. Implantable devices are required to remain in the patient post discharge for a period of 30 days. In most cases, the valve will remain in the patient for up to 6 weeks. Depending on the intent of this procedure, the physician may determine, based on their clinical judgment, if the case fits the requirement for classifying this device as an implantable device.

#### **Olympus Reimbursement Resources**



# **OLYMPUS UNITE Reimbursement Helpline Contact Information**

Phone: 877-205-1532 Hours: 8:30 am - 5:00 pm Eastern Time Email: <u>Olympusunite@priahealthcare.com</u>

# **OLYMPUS UNITE Reimbursement Helpline Services**

- Review of the HDE process and payer submission materials.
- Identification of the correct coding for Spiration Valve System.
- Assistance with determining prior authorization polices.
- Review of your local payer's specific coverage and reimbursement criteria.
- Provision of additional details relating to medical documentation.
- Review of payer explanation for denied or underpaid claims.
- Review of coding errors related denials and guidance on how to resubmit or appeal the claim.

# Spiration<sup>™</sup> Valve System for Management of Air Leaks

# **Supporting Documentation**

ATTACHMENT A:	FDA HDE Approval Letter
ATTACHMENT B:	Requesting Prior Authorization
ATTACHMENT C:	Sample Letter of Medical Necessity
ATTACHMENT D:	Instructions For Use – Spiration Valve System
ATTACHMENT E:	Instructions For Use – Airway Sizing Kit
ATTACHMENT F:	Spiration Valve System Procedure Overview

# **Supporting Documentation**

# A: FDA HDE Approval Letter

	Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-C Silver Spring, MD 20993-0002
August 17, 2015	
Cyndy Adams	
Senior Regulatory Affairs Manager	
6675 185 <sup>th</sup> Avenue N.E.	
Redmond, WA 98052	
Re: H060002 S007	
Spiration Valve System	
Filed: February 6, 2015	
Amended: June 4, 2015	
Dear Ms. Adams:	
The Center for Devices and Radiological Health (CDRH) or (FDA) has completed its evaluation of your humanitarian de supplement, which requested approval for a modified versi- introduce a 9mm valve. The device, as modified, will be m Spiration Valve System and is indicated for control prolong air leaks that are likely to become prolonged air leaks follow lung volume reduction surgery (LVRS). An air leak present prolonged unless present only during forced exhalation or co- should be considered for treatment if it is: 1) continuous, 2) phase of inspiration, or 3) present upon normal expiration ai emphysema or respiratory compromise. Spiration Valve Sy prolonged air leak. Based upon the information submitted, subject to the conditions described in the approval order for commercial distribution of the device as modified by your F letter.	f the Food and Drug Administration evice exemption application (HDE) on of the reloadable catheter and to arketed under the trade name ed air leaks of the lung, or significant ving lobectomy, segmentectomy, or on post-operative day 7 is considered ough. An air leak present on day 5 present during normal inhalation nd accompanied by subcutaneous stem use is limited to 6 weeks per the HDE supplement is approved your original HDE. You may begin HDE supplement upon receipt of this
rener.	escription use in accordance with 21
The sale, distribution, and use of this device are limited to pro CFR 801.109 within the meaning of section 520(e) of the Fec (the FD&C Act) under the authority of section 515(d)(1)(B)(i order to ensure the safe use of the device, FDA has further res of section 520(e) of the FD&C Act under the authority of sec insofar as the sale, distribution, and use must not violate section	escription use in accordance with 21 leral Food, Drug, and Cosmetic Act i) of the FD&C Act. In addition, in stricted the device within the meaning tion $515(d)(1)(B)(ii)$ of the FD&C Act ons $502(a)$ and (t) of the FD&C Act

# **Supporting Documentation**

# A: FDA HDE Approval Letter (Continued)

Page 2 - Ms. Adams

under 21 CFR 814.126, at intervals of one year (unless otherwise specified) from the date of approval of the original HDE. Two copies of this report, identified as "<u>Annual Report</u>" and bearing the applicable HDE reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.126.

In addition to the above, an HDE holder is required to maintain records of the names and addresses of the facilities to which the HUD has been shipped, correspondence with reviewing institutional review boards (IRBs), as well as any other information requested by a reviewing IRB or FDA.

This is a reminder that as of September 24, 2014, class III devices are subject to certain provisions of the final UDI rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). For more information on these requirements, please see the UDI website, <a href="http://www.fda.gov/udi">http://www.fda.gov/udi</a>.

Before making any change affecting the safety or effectiveness of the device, you must submit an HDE supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39 except a request for a new indication for use of for a humanitarian use device (HUD). A request for a new indication for use for an HUD shall comply with the requirements set forth in 21 CFR 814.110 which includes obtaining a new designation of HUD status for the new indication for use and submission of an original HDE application in accordance with §814.104. The application for the new indication for use may incorporate by reference any information or data previously submitted to the agency.

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

- 1. May have caused or contributed to a death or serious injury; or
- 2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a>.

In accordance with the recall requirements specified in 21 CFR 806.10, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to:

# **Supporting Documentation**

# A: FDA HDE Approval Letter (Continued)



# **Supporting Documentation**

# **B: Requesting Prior Authorization**

Prior authorization is a process that varies among different payers. It is always best to contact your payer representative to obtain a thorough understanding of the steps involved in making a prior authorization request. Here are some common requirements in obtaining prior authorization. The key in all coding and billing to payers is to be truthful and not misleading and make full disclosures to the payer about how the product has been used and the procedures necessary to deploy and remove the product when seeking reimbursement for any product or procedure.

#### Documentation

Identify the documentation that the payer requires in order to review the prior authorization request. Generally, a letter of medical necessity is needed. This document summarizes the rationale for the payer to provide coverage for the therapy in question.

#### **Request Routing**

Ensure that you understand who will review your request and how to route your request to the payer's review staff. Some departments provide specific routing instructions and have a preference for fax, email or written correspondence. Requests are easily misplaced. Please follow-up with review staff to ensure your request has been received and periodically thereafter to ensure the request is being addressed.

#### Timelines

When speaking to the payer representative, clarify the timeframe in which original documentation and supplemental documents must be provided and how long it will take to receive an answer. Requests may be rejected if the applicant is not diligent in responding to requests for additional information.

#### Denials

Determine your avenues for payer appeal if the prior authorization is denied. Most payers have multiple levels of appeal that allow for review by different internal bodies. An initial denial can be subsequently overturned on appeal.

#### Recertification

When a prior authorization request has been approved, be aware that some decisions may have a limited timeframe for which the approval is effective. In some cases, recertification may be necessary if the initial timeframe is exceeded.

# **Supporting Documentation**

# **C: Sample Letter Of Medical Necessity**

NOTE: The text below is only a guide and should not be replicated verbatim. Customize to individual patient and clinical opinions/justification.

## [DATE]

[prior authorization fax number or mailing address] Patient Name: [Patient Name} Member ID#: [Member ID] Date of Birth:

Date of Service : [MM/DD/YYYY] Place of Service: [Facility/Hospital Name], [Street address], [City], [State], [Zip] Performing physician: [Physician Name], [NPI]

CPT Codes: [Insert CPT Codes] ICD-9- Procedure code: [Insert ICD-9 Procedure codes] Diagnosis codes: [Insert diagnosis codes]

Prior Authorization for coverage for the assessment, insertion and removal of the Spiration Valve System

Dear [RECIPIENT],

I am writing to request a prior approval for coverage of the Spiration Valve System for treatment of a postoperative air leak. [Patient Name] has been diagnosed with [insert specific air leak diagnosis code description] on postoperative day [insert day]. The patient's current status is [insert detail of impairment and how it impacts quality of life, caregiver employment, etc].

It is my expert medical opinion that a prolonged hospital stay is not in the best interest of this patient's health and the placement of the Spiration Valve System will speed recovery and discharge from the hospital. The Spiration valves are delivered via a minimally invasive procedure that has shown to reduce or stop air leaks by limiting airflow to the damaged tissue. Given the condition of my patient I do not believe any other option will resolve their current medical issue.

A landmark study published in the European Respiration Journal demonstrated the use of the Spiration Valve as a safe and effective treatment for patients suffering from prolonged air leaks after anatomic resection of the lung.<sup>1</sup> After placement of the Spiration Valves, patients in the study experienced air leak cessation at a median of two days and chest tube removal at a median of four days. During the entire study there were no deaths, cardiovascular complications, or implant-related events such as infection distal to valve, lobar atelectasis, hemoptysis, pneumothorax or expectoration.<sup>1</sup>

The Spiration Valve System has been available in the United States under Humanitarian Device Exemption since October 2008.

Based on the above information and my medical judgment, I recommend the use of the Spiration Valve in this patient for the control of his/her prolonged air leak and improvement in their clinical course.

# **Supporting Documentation**

# **C: Sample Letter Of Medical Necessity (Continued)**

#### NOTE: The text below is only a guide and should not be replicated verbatim. Customize to individual patient and clinical opinions/justification.

We are requesting confirmation that this treatment be considered a covered benefit based on medical necessity and that associated professional fees for the procedure and follow-up will be covered. I ask that you concur with this rationale and consider the [PROCEDURE] using the Spiration Valve System and its associated materials and services to be a covered benefit for [PATIENT'S NAME].

I am enclosing a summary of procedures and dates of service that [PATIENT'S NAME] has already undergone and a bibliography of clinical literature supporting the use of the Spiration Valve System. [Note if relevant: prior treatments and outcomes, additional information on the patient's history and implications of prolongation of the air leak. A timeline is useful.]

I would like to sincerely thank you for taking the time to review this information and for considering coverage. If you have any questions, please feel free to contact me so that I can be of further assistance.

Sincerely, [SIGNATURE]

Dooms C, Decaluwe H, Yserbyt J, et al. Bronchial valve treatment for pulmonary air leak after anatomic lung resection for cancer. Eur Respir J 2014;43(4):1142-8.

## Caution

The Spiration Valve System is indicated to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged air leaks, following lobectomy, segmentectomy, or Lung Volume Reduction Surgery (LVRS). An air leak present on postoperative day 7 is considered prolonged unless present only during forced exhalation or cough. An air leak present on day 5 should be considered for treatment if it is: 1) continuous, 2) present during normal inhalation phase of inspiration, or 3) present upon normal expiration and accompanied by subcutaneous emphysema or respiratory compromise. Spiration Valve System use is limited to 6 weeks per prolonged air leak. The effectiveness of this device for this use has not been demonstrated.

Humanitarian Device. Authorized by Federal Law for use in the control of prolonged air leaks of the lung or significant air leaks that are likely to become prolonged following lobectomy, segmentectomy or Lung Volume Reduction Surgery (LVRS). The effectiveness of this device for this use has not been demonstrated. Federal law restricts this device to sale by or on the order of a physician.

#### Contraindications

Patient is unable to tolerate a flexible bronchoscopy procedure. Allergy to latex and nickel.

#### Warnings

Atelectasis may occur after the air leak seals and patients should be monitored for this possible complication.

#### **General Precautions**

The Spiration Valve System should not be used for patients who have active asthma, bronchitis or clinically significant bronchiectasis. Only use a bronchoscope with a working channel of 2.6mm or larger. Do not use the Spiration Valve System for other than its intended use. Potential Adverse Effects: Atelectasis; Death; Infection in the tissue distal to a valve; Local airway swelling or edema at site of valve implantation; Pneumothorax.

For full prescribing information go to: svs.olympusamerica.com

# **Supporting Documentation**

# **D: Instructions For Use – Spiration Valve System**



# **Supporting Documentation**

# D: Instructions For Use – Spiration Valve System (Continued)

#### 10 Operator's Instructions

- 10.1 Isolating the Air Leak by Balloon Occlusion
- servation of air bubbles passing through the water seal system connected to the chest tube(s) is a tool for asuring air leaks (it shows presence, size, and changes).
- Insert the ballion catheter into the instrument channel of the bronchoscope. Refer to the instruction for Use provided with the ballion catheter for its operation. Start in proximal airways before moving distally, as needed 2. Evaluate 1 in a airway segment contributes to the air leak by slowly inflating the balloon until the ballion seals provided with the balloon catheter for its operation. Start in proximal airways before moving disality, as needs 6. Sealukate if an airway segment contributions to the air leak by clowiny initiating the balloon until the balloon seal. the airway, Then, determine if the air leak has decreased or stopped. If the air leak has not decreased or stopped, deltate the balloon, pull the balloon catheter into the bronchoscope, and evaluate the next airway segment. If the air leak has decreases or stopp, this incidease the airway contributes to the air leak. Follow airway skizing instructions for appropriate value placement. S Matige airways may contribute to an itek. Additional balloon cocluptions and value inducements much are ensured.

#### n air leak. Additional balloon occlusions and valve placements may be required.

- 10.2 Selecting the Spiration Valve Size Use a balloon catheter (B5-2C) together with the Airway Sizing Kit to determine the appropriate valve size to use e a balloon catheter (B5-2C) togeעופה אי.... each target airway. aution: Incorrect valve size will reduce device effectiveness.
- 10.3 Loading the Spiration Valve
- Remove the isader and canteer from the pax-aging.
   Release the disposable shipping lock from the loader by pushing the catheter release safety slider forward, then pressing the catheter release builds of cake.
   Caution: If a "click" is not heard, fully re-insert the shipping lock into the loader. Repeat step 2.
- Using it a click is not nearor, using re-insert the supporting lock into the loader. Hepeat step 2. I the loader plunger all the way back. move the catheter from the protective tube in the packaging. act a catridge of the determined valve size. Remove the cartridge from the packaging. Verify a valve is de the cartridge (see Figure 3).



#### Figure 3: Spiration Valve and Cartridge

- non-val-opmation reare and Cartrage 3. Insert the cartridge into the loader until it locks into place. 7. Verify the catheter retractor is fully forward and the green safety clip is installed over the yellow portion of the handle.
- Inspect the catheter's distal tip for damage prior to inserting it into the loader. Damage may include kill deformation, tears, or protrusions. If the catheter is damaged, use a new catheter.
- theter as shown in Figure 4 so that it can be fully inserted into the loader without kinking or re is a depth gauge (see Figure 4) on the side of the loader that shows where the catheter sh while inserting it into the loader.



#### th gauge on loader used to determine where to grasp E

- Insert the catheter into the loader until an audible "click" is heard. Caution: If a "click" is not heard, release the catheter by pushing the catheter release safety slider forward, then pressing the catheter release button down until an audible "click" is heard. Remove the catheter from the loader. Repeat step 8. Not hearing a "click" when inserting the catheter winto the loader means the catheter has not been properly locked in on place inside the loader and the valvee may not load or properly. Caution: If a "click" is r then pressing the cather loader. Repeat step 8. not been properly locks
- Fully push the loader plunger to load the valve into the catheter. Verify that the plunger cannot be pushed any further.

- Verify that the plunger cannot be pushed any further. Release the catheter treates safety sider forward, then pressing the catheter release buttor down until an audite' cirk's' is heard. Remove the catheter from the loader. **Visually ingest the catheter** (is neares) that the value is loaded correctly. **Valually** ingest that catheter (is neares) that the value is loaded correctly. **Valually** ingest that be replaced. Pull the catheter fixed no replace that which is loaded to be replaced. Pull the to catheter was more than the replaced. Pull the catheter fixed no replace that which is cloaded the new value into the planeter box replaced. Pull the deplacet value. Obtain a new cathidge and load the new value into the sind the transmitter outport. way back and remove the cartridge

- 10.4 Deployment of the Spiration Valve 1. While holding the catheter at the proximal end of the catheter tip, carefully insert the catheter into the instrument channel of the bronchescope using slow, short strokes.
- Important:
- Inscittabi Only use a bronchoscope with an instrument channel inner diameter of 2.8 mm or larger. Do not bend or force the distal and of the catheter while inserting into the bronchoscope. This may cause a hish in the catheter which may prevent the valve form deploying. 2. While the bronchoscope is in a central airway without a bend, advance the catheter until the stabilization wire tip and removal or top are viable. **Caulton**, Applying accessive torse to advance the catheter through a bend in the bronchoscope could result in dimange b the catheter and/or the interment channel of the bronchoscope.
- Preparing to Advance the Catheter to the Target Location
- retract the catheter into the pronchoscope until to pronchoscope and does not interfere with its oper
- Positioning the Bronchoscope for Spiration Valve Deployment Under bronchoscopic observation. Advance and position the bronchoscope so that the target airway location is visible and the tip of the catheter can be directed into the target airway site without bending or kinking the catheter
- Advance the catheter so that the valve line passes beyond the target location.
- Caution: While directing the catheter to the target airway site, do not apply excessive force to advance the catheter.
- . sary to remove the loaded catheter from the bronchoscope, relax the bronc ope's distal
- 7. If the valve line is not at the desired target location, repeat steps 5 and 6. Performing steps 5 and 6 in sequence reduces movement of the catheter inside the bronchoscope channel during deployment.

# Deploying the Spiration Valve Inscrittin - The valve line and target location must be visible prior to deploying the valve. - Hold the catheter sheath at the bronchoscope instrument channel entry port to maintain the valve line at the target location, so the catheter does not move during deployment.

- target occiaion, so the cameer one no move summing oppoyment. 6. Order bronchoscopic observation, using a smooth continuus anchion, puil on the catheter intractor to deploy the value. Forcisio on the catheter can be decreased by limiting bench in the bronchoscope and the catheter and ob yraciciting in a speed time the catheter eractor to pladed during decloyment. 8. Once the value is completely displayed, immediately remove the catheter from the bronchoscope. 10. While hiding the catheter uncelled, advance the catheter eractor and er-install the safety catheter 10. While hiding the catheter uncelled, advance the catheter entitions and eractors and the safety catheter advance to the catheter uncelled, advance the catheter entitions and eractors and the safety catheter.

- Checking Spiration Valve Placement <sup>11</sup> Vieually examine the valve for position and fit. The valve should be opened and opposing ag . Visually examine the varie for position and in the of the airway. <u>Caution:</u> If the position of the deployed valve is not optimal or appropriate, remove and properly dispose of the
- Caution: If the position of the deployment, evaluate the reduction of the air leak and determine if additional val deployed.
- oepuryse. J. As needed, repeat the loading and deployment steps for each additional valve required. Caution: The catheter and loader and catheter, as new catheter and deploy to 10 Waves. After 10 valves are loaded and deployed from a loader and catheter, use new catheter and valued. Using a catheter and loader more than 10 times may lead to system failure. Important: Ensure the catheter stelly of is installed onto the catheter first before loading the next valve.
- 11. Spiration Valve Removal

11.1 Recommended Use of ET Tube

11.1 Recommended Use of E1 Iube Removal of valves should be conducted under branchescopic observation. It is recommended that valves should be removed through an endotrazhea (E7) lube or other insbasion system that lacilities access to the Allows better countrol of the upper airvay and facilitates variation and ansentatesia • Facilitates the manipulation of the flexible branchescope into the areas where valves need to be removed • Facilitates the manipulation of the flexible branchescope into the areas where valves need to be removed • Facilitates removed of the valves by protecting the vocal core data of the structures of the upper airvays. The procedure can be performed without installous, but this decision should be made by the physician after the or she has accurate a white 6 pariand on VAN's bystem.

11.2 Removing the Spiration Valve
1. Insert the appropriate forceps (see Table 1) through the instrument channel of the bronchoscope, d
the forceps to the target location (see Instructions for Use provided by the forceps manufacturer).

#### Table 1: Forceps Selection

	Forceps	Neconiniended Ose	
	Cupped Biopsy When the removal rod tip can be visualized and access		When the removal rod tip can be visualized and accessed by the biopsy forceps
	Rat-Tooth Jaw Grasping	When the removal rod shaft is being grasped.	
	Pediatric Biopsy	When the maneuverability of the bronchoscope is limited by standard sized forceps but the removal rod tip can be visualized and grasped.	

2. Grasp the removal rod shaft or removal rod tip with the appropriate forceps and gently pull the valve until it is dislodged from the airway wall. Use care to make sure that the removal rod does not get caught in the feneratration of the forcense when removing the valve (see Figure 5).



- прите из орнацион varive reemoval with Forceps Important; Before removing the valve from the trachea, pull the valve close to the end of the l (see Floure 6).



Arcept from the patient. Cautiant to hord attempt to bring the view to view through the instrument channel of the bronchoscope and the instrument channel of the bronchoscope. This instrument channel of the bronchoscope and the large attempt of the bronchoscope at the large attempt of the bronchoscope attempt of the large attempt

- Figure 6: Spiration Valve close to the end of the bronchoscope prior to rem
- While still firmly holding onto the valve with the forceps, simultaneously remove the bronchoscope and the forceps from the patient.

# **Supporting Documentation**

# **D: Instructions For Use – Spiration Valve System (Continued)**

able 3: Post Approval Study Me	thods and Results
	Study Methods
Objective	Characterize the safety profile of the Spiration Valve System
Design	Prospective Multi-Center Observational Study
	Inclusion Criteria - Subject has an air leak present on day 7 after lobectomy, segmentectomy, or lung volume reduction surgery (LVRS), or on days if the air lask is 1) continuous, 0) present during normal inhalation phase of inspiration, or 3) present upon normal separation and accompanied by subcutaneous emphysiema or respiratory compromise Exclusion Criteria
Study Population	Air leak only on force schalation or cough     Guiget has significant active asthma, pneuronia, bacterial bronchitis     or clinically significant bronchitestas     Guiget is surable to provide informed consent and there is no     designed a surfactly to sign for the incapacitated patient     Subject is not an appropriate candidate for, or unable to tolerate,     fexible bronchisscopy procedures     Subject has co-morbidites or factors that will prevent follow-up during the     study period
Data Source	Study specific case report forms
Key Study Endpoints	Adverse events reported during the study were analyzed and summarized.     Probable benefit information gathered during study was analyzed and summarized.
Number of Study Sites, Subjects, and Follow-up Rate	39 subjects were enrolled at 11 sites 100% (32/32 as per protocol)
Study Visits and Length of Follow-up	Following valve placement, subjects were followed through valve removal or 6 weeks, whichever was earlier
	Two schurzes events were reported for the 32 subjects treated
Final Safety Findings	1 systolic arrest occurred prior to valve placement; not device related     1 atelectasis and thick mucus secretion; possibly device related
Final Effectiveness Findings	<ul> <li>Of the 39 subjects enrolled, 32 received values (as per protocol); 7 subjects dia not receive values de tot inshifty to locates at reak (6), resolution of all reak (1), and inability to access at reak 30 (34%) (34%), and inshifty to access at reak 30 (34%) (34%), and the subject of the subjec</li></ul>
Study Strengths / Weaknesses	Strengths Prospective recruitment Prospective recruitment Torrough follow-up for adverse event determination Weaknesses Lack of control arm to determine underlying adverse event rate in population Lack of discrete secondary endpoints to evaluate efficacy Lankied discrete secondary endpoints to evaluate efficacy Lankied number of female patients (10), small sample size (22)
Patient Information Patient Information Pamphlet in System, Humanitarian Device for vallet card that indicates the pat	s available for potential patients (Patient Information for the Spiration Valve / Use in the Control of Air Leaks), Patients who receive treatment will be given a ient has valve(s) and lists the procedure doctor's contact information.

# **Supporting Documentation**

# E: Instructions For Use – Airway Sizing Kit



# **Supporting Documentation**

# E: Instructions For Use – Airway Sizing Kit (Continued)



# Spiration<sup>™</sup> Valve System for Management of Air Leaks

# **Supporting Documentation**

# F: Spiration Valve System Procedure Steps Overview







Airway Sizing



Airway Isolation



Valve Loading





Valve Placement

Valve Removal

Spiration<sup>™</sup> Valve System for Management of Air Leaks



Please see important Spiration<sup>™</sup> Valve System information on the next page.

#### **Spiration Valves**

A single-use, one-way bronchial valve preloaded in a disposable cartridge.

Catalog Number	Valve in Cartridge		
REF-HUS-V5	5 mm		
REF-HUS-V6	6 mm		
REF-HUS-V7	7 mm		
REF-HUS-V9	9 mm		
9 mm EE 21 12 mm	7 mm	6 mm	5 mm 01 8 mm

#### **Airway Sizing Kit**

A kit used to determine the appropriate valve size for each target airway.

 Catalog Number
 Kit Includes

 REF-HUS-VSK
 500 microliter glass syringe with a plunger, a calibration gauge, and a sizing worksheet

 Note: 1 Olympus B5-2C Disposable Balloon Catheter is shipped with each airway sizing kit

#### **Deployment Catheter and Loader**

A convenient deployment system for the delivery of multiple valves during a single patient procedure.

Catalog Number REF-HUS-C26N Bronchoscope Working Channel

2.6 mm or greater inner diameter

Deployment Catheter Length

1020 mm

#### Ancillary equipment needed for each procedure

- Flexible therapeutic bronchoscope with a working channel inner diameter of 2.6 mm or greater
- Bronchoscopy forceps appropriate for valve removal
- Standard 10cc sterile syringe with Luer-lock
- · Sterile saline (approximately 15–30cc used per procedure)
- A balloon catheter that inflates to 13 mm or larger (for balloon occlusion only)

Note: Products are supplied sterile

#### For Customer Support:

Email: **HUD-customersupport@olympus.com** Toll Free: **855-497-1616** Fax: **425-999-4545** 

# **To Request Technical Procedure Support:** Visit: **svs.olympusamerica.com/support**

#### For Reimbursement Support: Toll Free: 877-205-1532

Email: Olympusunite@priahealthcare.com

**Disclaimer:** The information presented here is for illustrative purposes only and does not constitute reimbursement or legal advice. The reimbursement information provided by Olympus America Inc. and/or its direct or indirect (through one or more intermediaries) parent companies, affiliates or subsidiaries (collectively, the "Olympus Group") is gathered from thirdparty sources and is subject to change without notice. Reimbursement rules vary widely by insurer so you should understand and comply with any specific rules that may be set by the patient's insurer. You must also understand and comply with Medicare's complex rules. It is the provider's sole responsibility to determine medical necessity and to in turn identify which CPT codes to report and to submit accurate claims. You should always consult with your local payers regarding reimbursement matters. Under no circumstances shall the Olympus Group or its employees, consultants, agents or representatives be liable for costs, expenses, losses, claims, liabilities or other damages (whether direct, indirect, special, incidental, consequential or otherwise) that may arise from or be incurred in connection with this information or any use thereof.

Coding recommendations, coverage policies, and reimbursement rates and methodologies vary by payer and are updated frequently. Providers should review applicable payer guidelines and instructions to ensure that billing practices comply with the payer's requirements and contact the payer if they have any questions. The American Medical Association (AMA) is responsible for development and maintenance of Current Procedural Terminology (CPT®) codes. Providers should check the complete AMA CPT reference manual and/or another authoritative source for a complete listing of all CPT codes and their descriptors. It is the provider's responsibility to report the code(s) that accurately describes the procedure(s) furnished and the patient's diagnosis. Please note that the presence of a code, or billing a particular code, is not a guarantee of payment. Reimbursement will vary for each provider based on a number of factors, including the payer, site of service, geographic location and contractual terms.

CPT is a registered trademark of the American Medical Association. Copyright 2019–2020, American Medical Association, all rights reserved. Applicable FARS/DFARS apply to government use.

**CAUTION:** Humanitarian Use Device. Authorized by Federal law for use in the control of prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged air leaks, following lobectomy, segmentectomy, or Lung Volume Reduction Surgery (LVRS). The effectiveness of this device for this use has not been demonstrated. Federal law restricts this device to sale by or on the order of a physician.

Olympus is a registered trademark of Olympus Corporation, Olympus America Inc., and/or their affiliates. 1 Medical devices listed may not be available for sale in all countries.



OLYMPUS AMERICA INC. 3500 Corporate Parkway, PO Box 610, Center Valley, PA 18034 For more information, contact your Olympus sales representative, or call 800-848-9024. www.medical.olympusamerica.com